JP7660077B2 - 診断方法 - Google Patents

診断方法 Download PDF

Info

Publication number
JP7660077B2
JP7660077B2 JP2021572701A JP2021572701A JP7660077B2 JP 7660077 B2 JP7660077 B2 JP 7660077B2 JP 2021572701 A JP2021572701 A JP 2021572701A JP 2021572701 A JP2021572701 A JP 2021572701A JP 7660077 B2 JP7660077 B2 JP 7660077B2
Authority
JP
Japan
Prior art keywords
adiponectin
antibody
polypeptide
levels
pancreatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021572701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529073A5 (https=
JP2022529073A (ja
Inventor
コステロ，エンヤ
グリーンハルフ，ウィリアム
オールドフィールド，ルーシー
ハロラン，クリストファー
ガネ・ポーラ
Original Assignee
ザ・ユニバーシティ・オブ・リバプール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1902193.0A external-priority patent/GB201902193D0/en
Priority claimed from GBGB1903424.8A external-priority patent/GB201903424D0/en
Application filed by ザ・ユニバーシティ・オブ・リバプール filed Critical ザ・ユニバーシティ・オブ・リバプール
Publication of JP2022529073A publication Critical patent/JP2022529073A/ja
Publication of JP2022529073A5 publication Critical patent/JP2022529073A5/ja
Application granted granted Critical
Publication of JP7660077B2 publication Critical patent/JP7660077B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/067—Pancreatitis or colitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2021572701A 2019-02-18 2020-02-17 診断方法 Active JP7660077B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1902193.0A GB201902193D0 (en) 2019-02-18 2019-02-18 Method of diagnosis
GB1902193.0 2019-02-18
GB1903424.8 2019-03-13
GBGB1903424.8A GB201903424D0 (en) 2019-03-13 2019-03-13 Method of diagnosis
PCT/EP2020/054046 WO2020169511A1 (en) 2019-02-18 2020-02-17 Method of diagnosis

Publications (3)

Publication Number Publication Date
JP2022529073A JP2022529073A (ja) 2022-06-16
JP2022529073A5 JP2022529073A5 (https=) 2023-02-17
JP7660077B2 true JP7660077B2 (ja) 2025-04-10

Family

ID=69591656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572701A Active JP7660077B2 (ja) 2019-02-18 2020-02-17 診断方法

Country Status (7)

Country Link
US (1) US20220091140A1 (https=)
EP (1) EP3903105A1 (https=)
JP (1) JP7660077B2 (https=)
CN (1) CN113454459A (https=)
AU (1) AU2020223826A1 (https=)
CA (1) CA3127569A1 (https=)
WO (1) WO2020169511A1 (https=)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016906A1 (fr) 2001-08-17 2003-02-27 Rebio Gen, Inc. Procede de diagnostic ou de controle d'une erreur du metabolisme du saccharose
JP2007525410A (ja) 2003-01-17 2007-09-06 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 膵臓癌に関連する抗原、それらに対する抗体、及び診断方法及び処置方法
JP2009528507A (ja) 2006-03-02 2009-08-06 オンコセラピー・サイエンス株式会社 Ｒｅｇ４タンパク質を用いて膵癌を診断する方法
JP2014508298A (ja) 2011-03-04 2014-04-03 イムノヴィア・アクチエボラーグ 方法、アレイ及びその使用
JP2014512808A (ja) 2011-03-04 2014-05-29 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
JP2017532633A (ja) 2014-08-14 2017-11-02 メメド ダイアグノスティクス リミテッド 多様体および超平面を用いる生物学的データのコンピュータ分析
US20170356908A1 (en) 2014-10-22 2017-12-14 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Blood biomarkers for appendicitis and diagnostics methods using biomarkers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
US8632983B2 (en) * 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
CN102939541B (zh) * 2010-06-15 2015-12-02 弗·哈夫曼-拉罗切有限公司 手术后急性肾损伤的预测和识别
JP2014510516A (ja) * 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
US20160231334A1 (en) * 2013-10-28 2016-08-11 The Forsyth Institute Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases
WO2015112429A1 (en) 2014-01-23 2015-07-30 Newomics Inc Methods and systems for diagnosing diseases
WO2015157557A1 (en) 2014-04-09 2015-10-15 Myriad Rbm, Inc. Methods of diagnosing pancreatic cancer and methods related thereto
WO2017019588A1 (en) * 2015-07-28 2017-02-02 The Johns Hopkins University Compositions and methods for detecting pancreatic cancer
GB201522839D0 (en) 2015-12-23 2016-02-03 Randox Lab Ltd And Randox Teoranta Method
US12416636B2 (en) * 2018-05-31 2025-09-16 University Of Florida Research Foundation, Inc. Personalized treatment of pancreatic cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016906A1 (fr) 2001-08-17 2003-02-27 Rebio Gen, Inc. Procede de diagnostic ou de controle d'une erreur du metabolisme du saccharose
JP2007525410A (ja) 2003-01-17 2007-09-06 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 膵臓癌に関連する抗原、それらに対する抗体、及び診断方法及び処置方法
JP2009528507A (ja) 2006-03-02 2009-08-06 オンコセラピー・サイエンス株式会社 Ｒｅｇ４タンパク質を用いて膵癌を診断する方法
JP2014508298A (ja) 2011-03-04 2014-04-03 イムノヴィア・アクチエボラーグ 方法、アレイ及びその使用
JP2014512808A (ja) 2011-03-04 2014-05-29 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
JP2017532633A (ja) 2014-08-14 2017-11-02 メメド ダイアグノスティクス リミテッド 多様体および超平面を用いる生物学的データのコンピュータ分析
US20170356908A1 (en) 2014-10-22 2017-12-14 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Blood biomarkers for appendicitis and diagnostics methods using biomarkers

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
C． HERDER et al.，Anti-inflammatory cytokines and risk of type-2 diabetes，Diabetes, Obesity and Metabolism，2013年，Vol.15, Suppl.3，pp.39-50
D． DRANKA-BOJAROWSKA et al.，The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen 19.9 in patients with pancreatic cancer and chronic pancreatitis，Journal of Physiology and Pharmacology，2015年，Vol.66, No.5，pp.653-663
Hye Won CHUNG et al.，Clinical significance of elevated serum soluble CD40 ligand levels as diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma，Journal of Translational Medicine，2014年，Vol.12, No.1，Article No.102
Irini CHATZIRALLI et al.，Model for Risk-Based Screening of Diabetic Retinopathy in People With Newly-Diagnosed Type 2 Diabetes Mellitus，Investigative ophthalmology & visual science，2017年05月01日，Vol.58, No.6，BIO99-BIO105
Jan SKRHA et al.，Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss，Pancreatology，2016年12月15日，Vol.17，pp.89-94
Kadri COLAKIGLU et al.，Role of adiponectin and leptin as diagnostic markers in pancreatic cancer，Bratislava Medical Journal，2017年07月24日，Vol.118, No.7，pp.394-398
Ming-Chu CHANG et al.，Adiponectin as a Potential Differential Marker to Distinguish pancreatic Cancer and Chronic Pancreatitis，Pancreas，2007年07月，Vol.35, No.1，pp.16-21
Ramesh KHADKA et al.，Risk factor, early diagnosis and overall survival on outcome of association between pancreatic cancer and diabetes mellitus: Changes and advances, a review，International Journal of Surgery，2018年04月，Vol.52，pp.342-346
T． KRECHLER et al.，Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus，Neoplasma，2011年，Vol.58, No.1，pp.58-64

Also Published As

Publication number Publication date
US20220091140A1 (en) 2022-03-24
CA3127569A1 (en) 2020-08-27
CN113454459A (zh) 2021-09-28
JP2022529073A (ja) 2022-06-16
WO2020169511A1 (en) 2020-08-27
AU2020223826A1 (en) 2021-08-05
EP3903105A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
Al-Sawaf et al. Body composition and lung cancer-associated cachexia in TRACERx
US20250216393A1 (en) Plasma autoantibody biomarkers for diagnosis of lung cancer
Rho et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer
JP6774925B2 (ja) 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療のための方法並びにそのキット
EP3073268A1 (en) Biomarker panel for diagnosing cancer
JP6983221B2 (ja) 大腸癌の併用検査
US20120309697A1 (en) Methods of diagnosing and prognosing colonic polyps
JP2018519499A (ja) 慢性腎疾患の発症のリスクを予測するための方法
Lipshitz et al. Emerging markers of cancer cachexia and their relationship to sarcopenia
WO2019048588A1 (en) PANEL OF PROTEIN BIOMARKERS AND MIXED AUTO-ANTIBODIES FOR THE DIAGNOSIS OF COLORECTAL CANCER
CN113785199B (zh) 用于诊断结肠直肠癌和/或其癌前阶段的蛋白质特征
JP2021144052A (ja) マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用
EP3835789A1 (en) Biomarker panel for diagnosing colorectal cancer
JP5704684B2 (ja) ＩｇＧ４関連疾患診断用マーカー及びその利用
Kovacevic et al. Urine proteomic analysis in cystinuric children with renal stones
US20190101540A1 (en) Angiogenesis Biomarkers Associated With Disease Progression in Lung Cancer
JP7660077B2 (ja) 診断方法
EP2895863B1 (en) New biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma
CN114286942B (zh) 检测癌症的方法
Shah et al. Serum glycoprotein biomarker validation for esophageal adenocarcinoma and application to Barrett’s surveillance
KR20240068432A (ko) 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트
Mohamed et al. Faculty of Graduate Studies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250331

R150 Certificate of patent or registration of utility model

Ref document number: 7660077

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150